tiprankstipranks
Trending News
More News >
Koninklijke Philips N.V. (DE:PHIA)
NYSE:PHIA

Koninklijke Philips (PHIA) Price & Analysis

Compare
44 Followers

PHIA Stock Chart & Stats

€24.00
€0.00(0.00%)
At close: 4:00 PM EDT
€24.00
€0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Installed-base Recurring RevenuePhilips’ business model benefits from an installed‑base flywheel: strong aftermarket services, software and consumables attachment create recurring revenue that cushions capital‑equipment cyclicality, improves revenue visibility and supports long‑term margin resilience.
Productivity And Cost SavingsSustained, material productivity delivery (over EUR2.5bn since 2023 with continued programs) structurally raises operating leverage potential, funds reinvestment and margin targets, and provides a durable mechanism to offset cost headwinds and support cash generation.
Innovation And Strategic M&AA deep innovation pipeline and targeted M&A expand clinical capabilities and product mix (MRI, spectral CT, AI navigation, intravascular imaging), strengthening competitive differentiation, enabling premium pricing and supporting sustainable revenue and gross‑margin improvement over time.
Bears Say
Respironics Legal/regulatory RiskThe Respironics recall and attendant regulatory probes create persistent legal, compliance and remediation costs, elevate reputational risk, and necessitate ongoing quality investments. These factors can drive multi‑year cash outflows and constrain operating focus and growth.
Tariff-driven Margin PressureSustained tariff exposure (EUR250–300m annualized) materially compresses margins unless fully mitigated, forcing pricing, localization or cost actions. It reduces margin carry‑through on growth and increases execution risk for multi‑year profitability targets.
Volatile Free Cash FlowFree cash flow has shown large swings driven by one‑offs and settlements, weakening predictability of internal funding for capex, R&D and dividends. This volatility raises refinancing and allocation risk and complicates delivery of multi‑year targets without continued non‑recurring relief.

Koninklijke Philips News

PHIA FAQ

What was Koninklijke Philips N.V.’s price range in the past 12 months?
Koninklijke Philips N.V. lowest stock price was €18.50 and its highest was €27.60 in the past 12 months.
    What is Koninklijke Philips N.V.’s market cap?
    Koninklijke Philips N.V.’s market cap is €22.90B.
      When is Koninklijke Philips N.V.’s upcoming earnings report date?
      Koninklijke Philips N.V.’s upcoming earnings report date is May 06, 2026 which is in 48 days.
        How were Koninklijke Philips N.V.’s earnings last quarter?
        Koninklijke Philips N.V. released its earnings results on Feb 10, 2026. The company reported €0.623 earnings per share for the quarter, beating the consensus estimate of €0.492 by €0.131.
          Is Koninklijke Philips N.V. overvalued?
          According to Wall Street analysts Koninklijke Philips N.V.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Koninklijke Philips N.V. pay dividends?
            Koninklijke Philips N.V. does not currently pay dividends.
            What is Koninklijke Philips N.V.’s EPS estimate?
            Koninklijke Philips N.V.’s EPS estimate is 0.22.
              How many shares outstanding does Koninklijke Philips N.V. have?
              Koninklijke Philips N.V. has 962,920,100 shares outstanding.
                What happened to Koninklijke Philips N.V.’s price movement after its last earnings report?
                Koninklijke Philips N.V. reported an EPS of €0.623 in its last earnings report, beating expectations of €0.492. Following the earnings report the stock price went up 13.115%.
                  Which hedge fund is a major shareholder of Koninklijke Philips N.V.?
                  Currently, no hedge funds are holding shares in DE:PHIA
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Koninklijke Philips N.V.

                    Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

                    Koninklijke Philips (PHIA) Earnings & Revenues

                    PHIA Company Deck

                    PHIA Earnings Call

                    Q4 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call conveys a broadly positive operational and financial performance: strong Q4 order intake and sales acceleration, substantial margin expansion, robust Personal Health and Connected Care momentum, significant productivity delivered and an active innovation pipeline. These positives are balanced by tangible near‑term headwinds — notably tariffs (annualized impact in 2026), ongoing Respironics‑related legal and regulatory matters, China tender dynamics, and some D&T margin pressure and Q1 phasing risk. Management has mitigations in place (productivity programs, pricing, localization) and a clear guide for 2026 (3%–4.5% sales growth; 12.5%–13% EBITDA margin), which supports confidence in execution despite the known risks.View all DE:PHIA earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Abbott Laboratories
                    Boston Scientific
                    Dexcom
                    Strata Skin Sciences
                    Stryker

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks